Impact of BTK Inhibition on Monocytic Myeloid-Derived Suppressor Cells in CLL

Video

Arantxa Romero-Toledo, PhD student, at the Centre for Haemato-Oncology, Barts Cancer Institute, discusses the impact of BTK inhibition on monocytic myeloid-derived suppressor cells (MDSCs) in chronic lymphocytic leukemia (CLL).

Arantxa Romero-Toledo, PhD student, at the Centre for Haemato-Oncology, Barts Cancer Institute, discusses the impact of BTK inhibition on monocytic myeloid-derived suppressor cells (MDSCs) in chronic lymphocytic leukemia (CLL).

In a study led by Romero-Toledo, investigators sought to evaluate MDSCs in CLL using a mouse model. First, investigators assessed granulocytic and monocytic MDSC populations upon progression. However, unlike in humans, the MDSC populations were lost upon disease progression, says Romero-Toledo; this was surprising as these populations were expected to accumulate. Investigators attributed this to the granulocytic population in peripheral blood.

After treatment with acalabrutinib (Calquence) and ibrutinib (Imbruvica), investigators reported that the monocytic population regrew in the spleen. As such, investigators believe there is a role for ITK inhibition in this population. However, ITK inhibition has only been reported with ibrutinib, not acalabrutinib. However, in terms of macrophages, acalabrutinib restored the population of macrophages in spleens, contrary to prior findings.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,